In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Dilemma in cardio-renal patients: hyperkalaemia vs renin-angiotensin-aldosterone system inhibitors?
Session

Event : Heart Failure 2018

Topic : Chronic Heart Failure: Comorbidities

  • Session type : Satellite Symposium
  • Date : 27 May 2018
  • Time : 14:45 - 15:45
  • Sponsored by Vifor Pharma

5 presentations in this session

Dilemma in cardio-renal patients: hyperkalaemia vs renin-angiotensin-aldosterone system inhibitors? - Introduction

Event : Heart Failure 2018

  • Session : Dilemma in cardio-renal patients: hyperkalaemia vs renin-angiotensin-aldosterone system inhibitors?
  • Speaker : J Cleland (Glasgow,GB)
  • Sponsored by Vifor Pharma

Renin-angiotensin-aldosterone system inhibitors therapy benefits and challenges in cardio-renal patients.

Event : Heart Failure 2018

  • Session : Dilemma in cardio-renal patients: hyperkalaemia vs renin-angiotensin-aldosterone system inhibitors?
  • Speaker : P Van Der Meer (Groningen,NL)
  • Sponsored by Vifor Pharma

Changing the treatment paradigm of hyperkalaemia management to enable and optimize renin-angiotensin-aldosterone system inhibitors therapy.

Event : Heart Failure 2018

  • Session : Dilemma in cardio-renal patients: hyperkalaemia vs renin-angiotensin-aldosterone system inhibitors?
  • Speaker : B Pitt (Ann Arbor,US)
  • Sponsored by Vifor Pharma

Panel discussion.

Event : Heart Failure 2018

  • Session : Dilemma in cardio-renal patients: hyperkalaemia vs renin-angiotensin-aldosterone system inhibitors?
  • Speaker : J Butler (Atlanta,US)
  • Sponsored by Vifor Pharma

Dilemma in cardio-renal patients: hyperkalaemia vs renin-angiotensin-aldosterone system inhibitors? - Summary and conclusions

Event : Heart Failure 2018

  • Session : Dilemma in cardio-renal patients: hyperkalaemia vs renin-angiotensin-aldosterone system inhibitors?
  • Speaker : J Cleland (Glasgow,GB)
  • Sponsored by Vifor Pharma

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are